Clinical Trial Update: Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

View source ↗

Summary

A clinical trial update examining the use of zanubrutinib and acalabrutinib in chronic B-cell malignancies and noting the risk of atrial fibrillation with BTK i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies
• Cardiovascular Diseases

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: University Hospital, Caen | Conditions: Chronic B-cell Malignancies, BTK Inhibitors | Status: NOT_YET_RECRUITING